{"organizations": [], "uuid": "c7b96f49e0440a478431a00b89360823ab80e5a2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180426.html", "section_title": "Archive News &amp; Video for Thursday, 26 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/shire-results/bid-target-shire-reports-6-pct-rise-in-first-quarter-earnings-idUSFWN1S30VL", "country": "US", "domain_rank": 408, "title": "Bid target Shire reports 6 pct rise in first-quarter earnings", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-26T19:15:00.000+03:00", "replies_count": 0, "uuid": "c7b96f49e0440a478431a00b89360823ab80e5a2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/shire-results/bid-target-shire-reports-6-pct-rise-in-first-quarter-earnings-idUSFWN1S30VL", "ord_in_thread": 0, "title": "Bid target Shire reports 6 pct rise in first-quarter earnings", "locations": [], "entities": {"persons": [{"name": "shire", "sentiment": "negative"}, {"name": "paul sandle", "sentiment": "none"}, {"name": "sarah young", "sentiment": "none"}], "locations": [{"name": "shire", "sentiment": "none"}, {"name": "london", "sentiment": "none"}, {"name": "japan", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "takeda pharmaceutical", "sentiment": "negative"}, {"name": "takeda", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "LONDON, April 26 (Reuters) - Shire, the London-listed drugmaker targeted by Takeda Pharmaceutical, reported a 6 percent rise in first-quarter earnings on Thursday, helped by higher product sales and a lower tax rate partially offset by lower gross margins.\nThe company reported non-GAAP diluted earnings per American Depository Share of $3.86 on revenue of $3.77 billion, slightly ahead of analysts’ forecasts of $3.72 billion.\nThe rare-disease specialist said on Wednesday it was willing to recommend a sweetened $64 billion offer from Japan’s Takeda , in what would be the biggest acquisition of a drug company since 2000.\nReporting by Paul Sandle; editing by Sarah Young\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-26T19:15:00.000+03:00", "crawled": "2018-04-27T17:09:17.004+03:00", "highlightTitle": ""}